Polydrug abuse: A review of opioid and benzodiazepine combination use

Drug and Alcohol Dependence

Volumn 125, Issue 1-2, 2012, Pages 8-18

  Jones, Jermaine D ^a   Mogali, Shanthi ^a   Comer, Sandra D ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Benzodiazepines; Heroin; Opioids; Polydrug abuse

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BROTIZOLAM; BUPRENORPHINE; DIAZEPAM; FLUMAZENIL; FLUNITRAZEPAM; LORAZEPAM; METHADONE; NALOXONE; NIMETAZEPAM; OPIATE; OXAZEPAM; TRIAZOLAM;

ADVERSE OUTCOME; ANXIETY DISORDER; CHRONIC PAIN; DEPRESSION; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG METABOLISM; DRUG MISUSE; DRUG OVERDOSE; DRUG POTENTIATION; DRUG SAFETY; HEALTH HAZARD; HEPATITIS C; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAINTENANCE THERAPY; MULTIPLE DRUG ABUSE; MUSCULOSKELETAL PAIN; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; VIRUS TRANSMISSION;

ANALGESICS, OPIOID; BENZODIAZEPINES; DRUG INTERACTIONS; HUMANS; OPIOID-RELATED DISORDERS; SUBSTANCE-RELATED DISORDERS;

EID: 84865005087     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.07.004     Document Type: Review

References (226)

1. Agmo A., Galvan A., Hcrcdia A., Morales M. Naloxone blocks the anti-anxiety but not the motor effects of benzodiazepines and pentobarbital: experimental studies and literature review. Psychopharmacology 1995, 120:186-194.
2. Academy of Pain Medicine (APM), American Pain Society (APS) The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin. J. Pain 1997, 13:6-8.
3. Ator N.A. Contributions of GABAA receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders. CNS Spectr. 2005, 10:31-39.
4. Ator N.A., Griffiths R.R. Self-administration of barbiturates and benzodiazepines: a review. Pharmacol. Biochem. Behav. 1987, 27:391-398.
5. Auriacombe M., Fatseas M., Dubernet J., Daulouede J.P., Tignol J. French field experience with buprenorphine. Am. J. Addict. 2004, 13:S17-S28.
6. Bachs L.C., Bramness J.G., Engeland A., Skurtveit S. Repeated dispensing of codeine is associated with high consumption of benzodiazepines. Nor. J. Epidemiol. 2008, 18:185-190.
7. Backmund M., Pfab R., Rupp P., Zilker T., Häufiger N. Intoxikationen Suchtkranker durch Drogen und psychotrope Substanzen. Notarzt 1999, 15:29-33.
8. Backmund M., Reimer J., Meyer K., Gerlach J.T., Zachoval R. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. Clin. Infect. Dis. 2005, 40:S330-S335.
9. Ballantyne J.C., LaForge K.S. Opioid dependence and addiction during opioid treatment of chronic pain. Pain 2007, 129:235-255.
10. Ballantyne J.C., Mao J. Opioid therapy for chronic pain. New Engl. J. Med. 2003, 349:1943-1953.
11. Bammer G., Dobler-Mikola A., Philip M., Strang J., Uchtenhagen A. The heroin prescribing debate: integrating science and politics. Science 1999, 284:1277-1278.
12. Barnas C., Rossmann M., Roessler H., Riemer Y., Fleischhacker W.W. Benzodiazepines and other psychotropic drugs abused by patients in a methadone maintenance program: familiarity and preference. J. Clin. Psychopharmacol. 1992, 12:397-402.
13. Bateson A.N. The benzodiazepine site of the GABAA receptor: an old target with new potential?. Sleep Med. 2004, 5:S9-S15.
14. Becker W.C., Sullivan L.E., Tetrault J.M., Desai R.A., Fiellin D.A. Non-medical use, abuse and dependence on prescription opioids among US adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend. 2008, 94:38-47.
15. Bleich A., Gelkopf M., Schmidt V., Hayward R., Bodner G., Adelson M. Correlates of benzodiazepine abuse in methadone maintenance treatment. A 1 year prospective study in an Israeli clinic. Addiction 1999, 94:1533-1540.
16. Bleich A., Gelkopf M., Weizman T., Adelson M. Benzodiazepine abuse in a methadone maintenance treatment clinic in Israel: characteristics and a pharmacotherapeutic approach. Isr. J. Psychiatry Relat. Sci. 2002, 39:104-112.
17. Bergman J., Johanson C.E. The reinforcing properties of diazepam under several conditions in the rhesus monkey. Psychopharmacology 1985, 86:108-113.
18. Bergman U., Griffiths R.R. Relative abuse of diazepam and oxazepam: prescription forgeries and theft/loss reports in Sweden. Drug Alcohol Depend. 1986, 16:293-301.
19. Bertalmio A.J., Woods J.H. Reinforcing effect ofalfentanil is mediated by mu opioid receptors: apparent pA2 analysis. J. Pharmacol. Exp. Ther. 1989, 251:455-460.
20. Boeuf O., Lapeyre-Mestre M. French Network of Centers for Evaluation and Information Pharmacodependence (CEIP). Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP survey. Drug Saf. 2007, 30:265-276.
21. Borron S., Monier C., Risede P., Baud F.J. Flunitrazepam variably alters morphine, buprenorphine, and methadone lethality in the rat. Hum. Exp. Toxicol. 2002, 21:599-605.
22. Bramness J.G., Kornør H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. Drug Alcohol Depend. 2007, 90:203-209.
23. Brands B., Blake J., Marsh D.C., Sproule B., Jeyapalan R., Li S. The impact of benzodiazepine use on methadone maintenance treatment outcomes. J. Addict. Dis. 2008, 27:37-48.
24. Breen C.L., Degenhardt L.J., Bruno R.B., Roxburgh A.D., Jenkinson R. The effects of restricting publicly subsidised temazepam capsules on benzodiazepine use among injecting drug users in Australia. Med. J. Aust. 2004, 181:300-304.
25. Broekkamp C.L., LePichon M., Lloyd K.G. Akinesia after locally applied morphine near the nucleus raphe pontis of the rat. Neurosci. Lett. 1984, 50:313-318.
26. Bruce R.D., Govindasamy S., Sylla S., Haddad M.S., Kamarulzaman A., Altice F. Case series of buprenorphine injectors in Kuala Lumpur, Malaysia. Am. J. Drug Alcohol Abuse 2008, 34:511-517.
27. Brugal M.T., Domingo-Salvany A., Puig R., Barrio G., De GarciaOlalla P., de la Fuente L. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction 2005, 100:981-989.
28. Campo-Soria C., Chang Y., Weiss D.S. Mechanism of action of benzodiazepines on GABAA receptors. Br. J. Pharmacol. 2006, 148:984-990.
29. Carraro G.E., Russi E.W., Buechi S., Bloch K.E. Does oral alprazolam affect ventilation? A randomized, double-blind, placebo-controlled trial. J. Psychopharmacol. 2009, 23:22-27.
30. Carrieri M.P., Amass L., Lucas G.M., Vlahov D., Wodak A., Woody G.E. Buprenorphine use: the international experience. Clin. Infect. Dis. 2006, 43:S197-S215.
31. Chan G.M., Stajic M., Marker E.K., Hoffman R.S., Nelson L.S. Testing positive for methadone and either a tricyclic antidepressant or a benzodiazepine is associated with an accidental overdose death: analysis of medical examiner data. Acad. Emerg. Med. 2006, 13:543-547.
32. Chang Y., Moody D.E. Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes. Eur. J. Clin. Pharmacol. 2005, 60:875-881.
33. Chen K.W., Berger C.C., Forde D.P., D'Adamo C., Weintraub E., Gandhi D. Benzodiazepine use and misuse among patients in a methadone program. BMC Psychiatry 2011, 11:90.
34. Cicero T.J., Inciardi J.A., Munoz A. Trends in abuse of oxycontin and other opioid analgesics in the United States: 2002-2004. J. Pain 2005, 6:662-672.
35. Coach W.F. Benzodiazepines: an overview. Epidemiologic Trends in Drug Abuse, December 1989, DHHS Publication No. (ADM) 91-1773 1990, Division of Epidemiology and Prevention Research, NIDA, Rockville, MD.
36. Cole J.O., Chiarello R.J. The benzodiazepines as drugs of abuse. J. Psychiatr. Res. 1990, 24(Suppl. 2):135-144.
37. Comer S.D., Ashworth J.B., Foltin R.W., Johanson C.E., Zacny J.P., Walsh S.L. The role of human drug self-administration in the development of medications. Drug Alcohol Depend. 2008, 96:1-15.
38. Comer S.D., Sullivan M.A., Whittington R.A., Vosburg S.K., Kowalczyk W.J. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology 2008, 33:1179-1191.
39. Cook S., Moeschler O., Katarzyna M., Yersin B. Acute opiate overdose: characteristics of 190 consecutive cases. Addiction 1998, 93:1559-1565.
40. Cooper S.J. Minireview. Benzodiazepine-opiate antagonist interactions in relation to feeding and drinking behavior. Life Sci. 1983, 32:1043-1051.
41. Corkery J.M., Schifano F., Ghodse A.H., Oyefeso A. The effects of methadone and its role in fatalities. Hum. Psychopharmacol. 2004, 19:565-576.
42. Crane E.H., Nemanski N. Demographic Characteristics of Benzodiazepine-involved ED Visits. The DAWN Report, July 2004, Office of Applied Studies 2004, US Substance Abuse and Mental Health Services Administration, Available online at http://dawninfo.samhsa.gov/ (accessed: 14.12.10).
43. Darke S., Hall G.W. Levels and correlates of polydrug use among heroin users and regular amphetamine users. Drug Alcohol Depend. 1995, 39:231-235.
44. Darke S.G., Hall W., Ross M., Wodak A. Benzodiazepine use and HIV risk taking behavior among injecting drug users. Drug Alcohol Depend. 1992, 31:31-36.
45. Darke S.G., Ross J. Polydrug dependence and psychiatric comorbidity among heroin injectors. Drug Alcohol Depend. 1997, 48:135-141.
46. Darke S.G., Ross J., Hall W.D. Benzodiazepine use among injecting heroin users. Med. J. Aust. 1995, 1162:645-647.
47. Darke S.G., Ross J., Hall W. Overdose among heroin users in Sydney, Australia: I. Prevalence and correlates of non-fatal overdose. Addiction 1996, 91:405-411.
48. Darke S.G., Ross J., Mills K., Teesson M., Williamson A., Havard A. Benzodiazepine use among heroin users: baseline use, current use and clinical outcome. Drug Alcohol Rev. 2010, 29:250-255.
49. Darke S.G., Ross J., Teesson M., Lynskey M. Health service utilization and benzodiazepine use among heroin users: findings from the Australian Treatment Outcome Study (ATOS). Addiction 2003, 98:1129-1135.
50. Darke S.G., Swift W., Hall W., Ross M. Drug use, HIV risk-taking and psychosocial correlates of benzodiazepine use among methadone maintenance clients. Drug Alcohol Depend. 1993, 34:67-70.
51. Doherty M.H. Benzodiazepine sedation in critically ill patients. AACN Clin. Issues 1991, 2:748-761.
52. Dingledine R., Iversen L.L., Breuker E. Naloxone as a GABA antagonist: evidence from iontophoretic, receptor binding and convulsant studies. Eur. J. Pharmacol. 1978, 47:19-27.
53. Du Pont R.L. Abuse of benzodiazepines: the problems and the solutions. Am. J. Drug Alcohol 1988, 14:1-69.
54. Duka T., Wtister M., Herz A. Benzodiazepines modulate striatal enkephalin levels via a GABAergic mechanism. Life Sci. 1980, 26:771-776.
55. Durbin C.G. Sedation in the critically ill patient. New Horiz. 1994, 1:64-74.
56. Eiroa-Orosa F.J., Haasen C., Verthein U., Dilg C., Schäfer I., Reimer J. Benzodiazepine use among patients in heroin-assisted vs. methadone maintenance treatment: findings of the German randomized controlled trial. Drug Alcohol Depend. 2010, 112:226-233.
57. Epstein J.F., Groerer J.C. Heroin Abuse in United States 1997, The National Clearing House of Alcohol and Drug Information, Retrieved on December 11, 2010 from: http://www.oas.samhsa.gov/treatan/treana11.htm.
58. Epstein D.H., Preston K.L., Jasinski D.R. Abuse liability, behavioral pharmacology, and physical dependence potential of opioids in humans and laboratory animals: lessons from tramadol. Biol. Psychol. 2006, 73:90-99.
59. Ernst E., Bartu A., Popescu A., Ileutt K., Hansson R., Plumley N. Methadone-related deaths in Western Australia 1993-99. Aust. N. Z. J. Public Health 2002, 26:364-370.
60. European Monitoring Center for Drug and Alcohol Dependence (EMCDDA) Trends in Injecting Drug Use in Europe 2010, Selected Issue: EMCDDA, Lisbon.
61. Faroqui M.H., Cole M., Curran J. Buprenorphine, benzodiazepines and respiratory depression. Anesthesia 1983, 38:1002-1003.
62. Farre M., Teran M., Roset P., Mas M., Torrens M., Camí J. Abuse liability of flunitrazepam among methadone-maintained patients. Psychopharmacology 1998, 140:486-495.
63. Fennesy M.R., Sawynok J. The effect of benzodiazepines on the analgesic activity of morphine and sodium salicylate. Arch. Int. Pharmacodyn. Ther. 1973, 204:77-85.
64. Fernández-Sobrino A.M., Fernández-Rodríguez V., López-Castro J. Benzodiazepine use in a sample of patients on a treatment program with opiate derivatives (PTDO). Adicciones 2009, 21:143-146.
65. Findley J.D., Robinson W.W., Peregrino L. Addiction to secobarbital and chlordiazepoxide in the rhesus monkey by means of a self-infusion preference procedure. Psychopharmacology 1972, 26:93-114.
66. Fishbain D.A., Rosomoff H.L., Rosomoff R.S. Drug abuse, dependence and addiction in chronic pain patients. Clin. J. Pain 1992, 8:77-85.
67. Forrest A.L. Buprenorphine and lorazepam. Anaesthesia 1983, 38:598.
68. Forsyth A.M., Farquhar D., Gemmell M., Shewan D., Davies J.B. The dual use of opioids and temazepam by drug injectors in Glasgow (Scotland). Drug Alcohol Depend. 1993, 32:277-280.
69. Gelkopf M., Bleich A., Hayward R., Bodner G., Adelson M. Characteristics of benzodiazepine abuse in methadone maintenance treatment patients: a 1year prospective study in an Israeli clinic. Drug Alcohol Depend. 1999, 55:63-68.
70. Gilson A.M., Ryan K.M., Joranson D.E., Dahl J.L. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J. Pain Symptom Manage. 2004, 28:176-188.
71. Gotestam K.G. Intragastric self-administration of medazepam in rats. Psychopharmacology 1973, 28:87-94.
72. Grass H., Behnsen S., Kimont H., Staak M., Kaferstein H. Methadone and its role in drug-related fatalities in Cologne 1989-2000. Forensic Sci. Int. 2003, 132:195-200.
73. Grass H., Sticht G. Drogentod nach Haftentlassung-Untersuchung am Beispiel der Grossstadt Köln. Suchtmed 2001, 3:97-100.
74. Griffiths R.R., Ator N. Benzodiazepine self-administration in animals and humans: a comprehensive literature review. Benzodiazepines: A Review of Research Results, 1980 1981, 22-36. NIDA Research Monograph, Government Printing Office, Washington, DC. S. Szara, J. Ludford (Eds.).
75. Griffiths R.R., Johnson M.W. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J. Clin. Psychiatry 2005, 66:31-41.
76. Griffiths R.R., Lukas S.E., Bradford D., Brady J.V., Snell J.D. Self-injection of barbiturates and benzodiazepines in baboons. Psychopharmacology 1981, 75:101-109.
77. Griffiths R.R., Weerts E.M. Benzodiazepine self-administration in humans and laboratory animals: implications for problems of long-term use and abuse. Psychopharmacology 1997, 134:1-37.
78. Griffiths R.R., Wolf B. Relative abuse liability of different benzodiazepines in drug abusers. J. Clin. Psychopharmacol. 1990, 10:237-243.
79. Grytten L. Alcohol and Drugs in Norway [Rusmidler i Norge 98] 1998, The Norwegian Directorate for the Prevention of Alcohol and Drug Problems: and the National Institute for Alcohol and Drug Research, Oslo.
80. Gueye P.N., Borron S.W., Risède P., Monier C., Buneaux F., Debray M., Baud F.J. Buprenorphine and midazolam act in combination to depress respiration in rats. Toxicol. Sci. 2002, 65:107-114.
81. Haney M., Spealman R. Controversies in translational research: drug self-administration. Psychopharmacology 2008, 199:403-419.
82. Hardo P.G., Kennedy T.D. Night sedation and arthritic pain. J. R. Soc. Med. 1991, 84:73-75.
83. Hartog J., Tusel D.J. Valium use and abuse by methadone maintenance clients. Int. J. Addict. 1987, 22:1147-1154.
84. Heltsley R., DePriest A., Black D.L., Robert T., Marshall L., Meadors V.M., Caplan Y.H., Cone E.J. Oral fluid drug testing of chronic pain patients. I. Positive prevalence rates of licit and illicit drugs. J. Anal. Toxicol. 2011, 35:529-540.
85. Herridge P., Gold M.S. Pharmacological adjuncts in the treatment of opioid and cocaine addicts. J. Psychoactive Drugs 1988, 20:233-242.
86. Ho I.K., Loh H.H., Way E.L. Pharmacological manipulation of GABA in morphine analgesia, tolerance and physical dependence. Life Sci. 1976, 18:1111-1114.
87. Hou R.H., Scaife J., Freeman C., Langley R.W., Szabadi E., Bradshaw C.M. Relationship between sedation and pupillary function: comparison of diazepam and diphenhydramine. Br. J. Clin. Pharmacol. 2006, 61:752-760.
88. Iguchi M.Y., Handelsman L., Bickel W.K., Griffiths R.R. Benzodiazepine and sedative use abuse by methadone maintenance clients. Drug Alcohol Depend. 1993, 32:257-266.
89. Iguchi M.Y., Griffiths R.R., Bickel W.K., Handelsman L., Childress A.R., McLellan A.T. Relative abuse liability of benzodiazepines in methadone maintained populations in three cities. NIDA Res. Monogr. 1989, 95:364-365.
90. Iribarne C., Dreano Y., Bardou L.G., Ménez J.F., Berthou F. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology 1997, 117:13-23.
91. Ito K., Yoshikawa M., Maeda M., Jin X.L., Takahashi S., Matsuda M., Tamaki R., Kobayashi H., Suzuki T., Hashimoto A. Midazolam attenuates the antinociception induced by d-serine or morphine at the supraspinal level in rats. Eur. J. Pharmacol. 2008, 586:139-144.
92. Jasinnski D.R., Preston K.L. Comparison of intravenously administered methadone, morphine and heroin. Drug Alcohol Depend. 1986, 17:301-310.
93. Joranson D.E., Ryan K.M., Gilson A.M., Dahl J.L. Trends in medical use and abuse of opioid analgesics. JAMA 2000, 283:1710-1714.
94. Kerr T., Marsh D., Li K., Montaner J., Wood E. Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver. Drug Alcohol Depend. 2005, 80:329-335.
95. Kieffer B.L., Gavériaux-Ruff C. Exploring the opioid system by gene knockout. Prog. Neurobiol. 2002, 66:285-306.
96. Kilicarslan T., Sellers E.M. Lack of interaction of buprenorphine with flunitrazepam metabolism. Am. J. Psychiatr. 2000, 157:1164-1166.
97. King S.A., Strain J.J. Benzodiazepine use by chronic pain patients. Clin. J. Pain 1990, 6:143-147.
98. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci. Int. 2001, 121:65-69.
99. KIeber H.D., Gold M.S. Use of psychotropic drugs in treatment of methadone maintained narcotic addicts. Ann. N.Y. Acad. Sci. 1978, 311:81-98.
100. Klee H., Faugier J., Hayes C., Boulton T., Morris J. AIDS-related risk behaviour, polydrug use and temazepam. Br. J. Addict. 1990, 85:1125-1132.
101. Kouyanou K., Pither C.E., Wessely S. Medication misuse, abuse and dependence in chronic pain patients. J. Psychosom. Res. 1997, 43:497-504.
102. Kristensen Ø., Lølandsmo T., Isaksen A., Vederhus J.K., Clausen T. Treatment of polydrug-using opiate dependents during withdrawal: towards a standardisation of treatment. BMC Psychiatry 2006, 15:54.
103. LaBuda C.J., Fuchs P.N. The anxiolytic effect of acute ethanol or diazepam exposure is unaltered in μ-opioid receptor knockout mice. Brain Res. Bull. 2001, 55:755-760.
104. Laqueille X., Launay C., Dervaux A., Kanit M. Abuse of alcohol and benzodiazepine during substitution therapy in heroin addicts: a review of the literature. Encephale 2009, 35:220-225.
105. Lavie E., Fatseas M., Denis C., Auriacombe M. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence. Drug Alcohol Depend. 2009, 99:338-344.
106. Lee H.Y., Li J.H., Wu L.T., Wu J.S., Yen C.F., Tang H.P. Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan. Subst. Abuse Treat. Prev. Policy 2012, 7:11.
107. Licata S.C., Rowlett J.K. Abuse and dependence liability of benzodiazepine-type drugs: GABAA receptor modulation and beyond. Pharmacol. Biochem. Behav. 2008, 90:74-89.
108. Lintzeris N., Mitchell T.B., Bond A., Nestor L., Strang J. Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. J. Clin. Psychopharmacol. 2006, 26:274-283.
109. Lintzeris N., Mitchell T.B., Bond A.J., Nestor L., Strang J. Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. Drug Alcohol Depend. 2007, 91:187-194.
110. Lintzeris N., Nielsen S. Benzodiazepines, methadone and buprenorphine: interactions and clinical management. Am. J. Addict. 2010, 19:59-72.
111. Liu S., Evans D.B., Wang R. Correlation of urinary excretion of methadone metabolites with methadone metabolism and analgesia in the rat. J. Pharmacol. Exp. Ther. 1978, 204:67-76.
112. Lopez F., Miller L.G., Thompson M.L., Schatzki A., Chesley S., Greenblatt D.J., Shader R.I. Chronic morphine administration augments benzodiazepine binding and GABAA receptor function. Psychopharmacology 1990, 101:545-549.
113. Lorens S.A., Sainati S.M. Naloxone blocks the excitatory effect of ethanol and chiordiazepoxide on lateral hypothalamic self-stimulation behavior. Life Sci. 1978, 23:1359-1364.
114. Low K., Crestani F., Keist R., Benke D., Brünig I., Benson J.A., Fritschy J.M., Rülicke T., Bluethmann H., Möhler H., Rudolph U. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000, 290:131-134.
115. Lynch W.J., Carroll M.E. Regulation of drug intake. Exp. Clin. Psychopharmacol. 2001, 9:131-143.
116. Mak K.H., Wang Y.T., Cheong T.H., Poh S.C. The effect of oral midazolam and diazepam on respiration in normal subjects. Eur. Respir. J. 1993, 6:42-47.
117. Mantegazza P., Tammiso R., Vicentini L., Zambotti F., Zonta N. Muscimol antagonism of morphine analgesia in rats. Br. J. Pharmacol. 1979, 67:103-107.
118. Matthes H.W., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dollé P., Tzavara E., Hanoune J., Roques B.P., Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996, 383:819-823.
119. McCormick G.Y., White W.J., Zagon I.S., Lang C.M. Effects of diazepam on arterial blood gas concentrations and pH of adult rats acutely and chronically exposed to methadone. J. Pharmacol. Exp. Ther. 1984, 230:353-359.
120. McDuff D.R., Schwartz R., Tommasello A., Tiegel S., Donovan T., Johnson J.L. Outpatient benzodiazepine detoxification procedure for methadone patients. J. Subst. Abuse Treat. 1993, 10:297-302.
121. McGregor C., Machin A., White J.M. In-patient benzodiazepine withdrawal: comparison of fixed and symptom-triggered taper methods. Drug Alcohol Rev. 2003, 22:175-180.
122. McKernan R.M., Rosahl T.W., Reynolds D.S., Sur C., Wafford K.A., Atack J.R., Farrar S., Myers J., Cook G., Ferris P., Garrett L., Bristow L., Marshall G., Macaulay A., Brown N., Howell O., Moore K.W., Carling R.W., Street L.J., Castro J.L., Ragan C.I., Dawson G.R., Whiting P.J. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor alpha1 subtype. Nat. Neurosci. 2000, 3:587-592.
123. Me'garbane B., Buisine A., Jacobs F., Re'sie're D., Chevillard L., Vicaut E., Baud F.J. Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment. J. Subst. Abuse Treat. 2010, 38:403-407.
124. Megarbane B., Pirnay S., Borron S.W., Trout H., Monier C., Risède P., Boschi G., Baud F.J. Flunitrazepam does not alter cerebral distribution of buprenorphine in the rat. Toxicol. Lett. 2005, 57:211-219.
125. Meiler A., Mino A., Chatton A., Broers B. Benzodiazepine use in a methadone maintenance programme: patient characteristics and the physician's dilemma. Schweiz. Arch. Neurol. Psychiatr. 2005, 156:310-317.
126. Metzger D., Woody G., De Philippis D., McLellan A.T., O'Brien C., Platt J.J. Risk factors for needle sharing among methadone-treated patients. Am. J. Psychiatr. 1991, 148:636-640.
127. Middleton L.S., Nuzzo P.A., Lofwall M.R., Moody D.E., Walsh S.L. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction 2011, 106:1460-1473.
128. Mikolaenko I., Robinson C.A., Davis G.G. A review of methadone deaths in Jefferson County, Alabama. Am. J. Forensic Med. Pathol. 2002, 23:299-304.
129. Moody D.E. Drug interactions with benzodiazepines:epidemiologic correlates with other CNS depressants and in vitro correlates with inhibitors and inducers of cytochrome P450 3A4. Handbook of Drug Interactions: A Clinical and Forensic Guide 2004, 3-88. Humana Press Inc., Totowa. A. Mozayani, L.P. Raymon (Eds.).
130. Moroni F., Cheney D.L., Peralta E., Costa E. Opiate receptor agonists as modulators of γ-aminobutyric acid turnover in the nucleus caudatus, globus pallidus and substantia nigra of the rat. J. Pharmacol. Exp. Ther. 1978, 207:870-877.
131. Nader A. Behavioral effects of chronic buspirone administration in the pigeon: comparison to midazolam. Pharmacol. Biochem. Behav. 1991, 38:611-616.
132. Navaratnam V., Koong K. Adjunctive drug use among opiate addicts. Curr. Med. Res. Opin. 1990, 11:611-619.
133. Negus S.S., Henriksen S.J., Mattox A., Pasternak G.W., Portoghese P.S., Takemori A.E., Weinger M.B., Koob G.F. Effect of antagonists selective for mu, delta and kappa opioid receptors on the reinforcing effects of heroin in rats. J. Pharmacol. Exp. Ther. 1993, 265:1245-1252.
134. New York City Department of Health and Mental Hygiene Epi Data Brief 2011, Office of Vital Statistics and Office of the Chief Medical Examiner, Retrieved on January 4, 2012 from: http://www.nyc.gov/html/doh/downloads/pdf/epi/databrief10.pdf.
135. National Center on Addiction and Substance Abuse at Columbia University You've Got Drugs: Prescription Drug Pushers on the Internet: 2006 Update 2006, Retrieved on June 12, 2012 from: http://www.casacolumbia.org/articlefiles/380-2007%20You %27ve%20Got%20Drugs%20IV.pdf.
136. National Institutes on Drug Abuse/National Institutes of Health/U.S.Dept of Health and Human Services Prescription and Over-the-Counter Medications 2009, Retrieved on November 15, 2011 from: http://www.drugabuse.gov/PDF/Infofacts/PainMed09.pdf.
137. Nielsen S., Dietze P., Lee N., Dunlop A., Taylor D. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in. Addiction 2007, 102:616-622.
138. Nielsen S., Taylor D.A. The effect of buprenorphine and benzodiazepines on respiration in the rat. Drug Alcohol Depend. 2005, 79:95-101.
139. Nurutdinova D., Abdallah A.B., Bradford S., O'Leary C.C., Cottler L.B. Risk factors associated with Hepatitis C among female substance users enrolled in community-based HIV prevention studies. BMC Res. Notes 2011, 4:126.
140. Oliver P., Keen J. Concomitant drugs of misuse and drug using behaviours associated with fatal opiate-related poisonings in Sheffield, UK, 1997-2000. Addiction 2003, 98:191-197.
141. Palaoglu O., Ayhan I.H. The possible role of benzodiazepine receptors in morphine analgesia. Pharmacol. Biochem. Behav. 1986, 90:244-246.
142. Panlilio L.V., Thorndike E.B., Schindler C.W. Lorazepam reinstates punishment-suppressed remifentanil self-administration in rats. Psychopharmacology 2005, 179:374-382.
143. Papworth D.P. High dose buprenorphine for postoperative analgesia. Anesthesia 1983, 38:163.
144. Passik S.D., Kirsh K.L., Donaghy K.B., Portenoy R.K. Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse. Clin. J. Pain 2006, 22:173-181.
145. Paulozzi L.J., Logan J.E., Hall A.J., McKinstry E., Kaplan J.A., Crosby A.E. A comparison of drug overdose deaths involving methadone and other opioid analgesics in West Virginia. Addiction 2009, 104:1541-1548.
146. Perret G., Déglon J.J., Kreek M.J., Ho A., La Harpe R. Lethal methadone intoxications in Geneva, Switzerland, from 1994 to 1998. Addiction 2000, 95:1647-1653.
147. Pick C.G. Antinociceptive interaction between alprazolam and opioids. Brain Res. Bull. 1997, 42:239-243.
148. Pirnay S., Borron S., Giudicelli C., Tourneau J., Baud F., Ricordel I. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone associated deaths. Addiction 2004, 99:978-988.
149. Poisnel G., Dhilly M., Le Boisselier R., Barre L., Debruyne D. Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J. Pharmacol. Sci. 2009, 110:36-46.
150. Pollini R.A., McCall L., Mehta S.H., Vlahov D., Strathdee S.A. Non-fatal overdose and subsequent drug treatment among injection drug users. Drug Alcohol Depend. 2006, 83:104-110.
151. Pond S.M., Tong T.G., Benowitz N.L., Jacob P., Rigod J. Lack of effect of diazepam on methadone metabolism in methadone-maintained addicts. Clin. Pharmacol. Ther. 1982, 31:139-143.
152. Preston K.L., Griffiths R.R., Cone E.J., Darwin W.D., Gorodetzky C.W. Diazepam and methadone blood levels following concurrent administration of diazepam and methadone. Drug Alcohol Depend. 1986, 18:195-202.
153. Preston K.L., Griffiths R.R., Stitzer M.L., Bigelow G.E., Liebson I.A. Diazepam and methadone interactions in methadone maintenance. Clin. Pharmacol. Ther. 1984, 36:534-541.
154. Preston K.L., Jasinski D.R. Abuse liability studies of opioid agonist-antagonists in humans. Drug Alcohol Depend. 1991, 28:49-82.
155. Primeaux S.D., Wilson S.P., McDonald A.J., Mascagni F., Wilson M.A. The role of delta opioid receptors in the anxiolytic actions of benzodiazepines. Pharmacol. Biochem. Behav. 2006, 85:545-554.
156. Puntillo K., Casella V., Reid M. Opioid and benzodiazepine tolerance and dependence: application of theory to critical care practice. Heart Lung 1997, 26:317-324.
157. Ravi N.V., Maany I., Burke W.M., Dhopesh V., Woody G. Detoxification with phenobarbitol of alprazolam-dependent polysubstance abusers. J. Subst. Abuse Treat. 1990, 7:55-58.
158. Reynaud M., Petit G., Potard D., Courty P. Six deaths linked to concomitant use of buprenoprhine and benzodiazepines. Addiction 1998, 93:1385-1392.
159. Rocha L., Tatsukawa K., Chugani H.T., Engel J. Benzodiazepine receptor binding following chronic treatment with naloxone, morphine and met-enkephalin in normal rats. Brain Res. 1993, 612:247-252.
160. Rooney S., Kelly G., Bamford L., Sloan D., O'Connor J.J. Co-abuse of opiates and benzodiazepines. Irish J. Psychol. Med. 1999, 168:36-41.
161. Rosenbaum J.F. Attitudes toward benzodiazepines over the years. J. Clin. Psychiatry 2005, 66:4-8.
162. Ross J., Darke S. The nature of benzodiazepine dependence among heroin users in Sydney, Australia. Addiction 2000, 95:1785-1793.
163. Ross J., Darke S., Hall W. Benzodiazepine use among heroin users in Sydney: patterns of use, availability and procurement. Drug Alcohol Rev. 1996, 15:237-243.
164. San L., Torrens M., Castillo C., Porta M., de la Torre R. Consumption of buprenorphine and other drugs among heroin addicts under ambulatory treatment: results from cross sectional studies in 1988-1990. Addiction 1993, 88:1341-1349.
165. Sasaki K., Fan L.W., Tien L.T., Ma T., Loh H.H., Ho I.K. The interaction of morphine and gamma-aminobutyric acid (GABA)ergic systems in anxiolytic behavior: using mu-opioid receptor knockout mice. Brain Res. Bull. 2002, 57:689-694.
166. Saunders P.A., Ho I.K. Barbiturates and the GABAA receptor complex. Prog. Drug Res. 1990, 34:261-286.
167. Schmidt-Kittler A., von Meyer L. Drogenbedingte Todesfälle 1998. Suchtmed 2000, 2:103-109.
168. Sekar M., Mimpriss T.J. Buprenorphine, benzodiazepines and prolonged respiratory depression. Anaesthesia 1987, 42:567-568.
169. Shah N.S., Patel V.O., Donald A.G. Effect of diazepam, desmethylimipramine, and SKF 525-A on the disposition of levo-methadone in mice after single or double injection. Drug Metab. Dispos. 1979, 7:241-242.
170. Sigg E.B., Keim K.L., Kepner K. Selective effect of diazepam on certain central sympathetic components. Neuropharmacology 1971, 10:621-629.
171. Sivam S.P., Ho I.K. GABA in morphine analgesia and tolerance. Life Sci. 1985, 37:199-208.
172. Skatrud J.B., Begle R.L., Busch M.A. Ventilatory effects of single, high-dose triazolam in awake human subjects. Clin. Pharmacol. Ther. 1988, 44:684-689.
173. Skurtveit S., Furu K., Bramness J., Selmer R., Tverdal A. Benzodiazepines predict use of opioids: a follow-up study of 17,074 men and women. Pain Med. 2010, 11:805-814.
174. Soria C., Fernandez-Lopez A., Gomez T., Calvo P. [3H]-flunitrazepam binding after morphine treatment and under abstinence syndrome. Brain Res. Bull. 1991, 27:611-615.
175. Soubrie P., Jobert A., Thiebot M.H. Differential effects of naloxone against the diazepam-induced release of behavior in rats in three aversive situations. Psychopharmacology 1980, 69:101-105.
176. Spaulding T.C., Minium L., Kotake A.N., Takemori A.E. The effect of diazepam on the metabolism of methadone by the liver of methadone dependent rats. Drug Metab. Dispos. 1974, 12:458-463.
177. Specka M., Bonnet U., Heilmann M., Schifano F., Scherbaum N. Longitudinal patterns of benzodiazepine consumption in a German cohort of methadone maintenance treatment patients. Hum. Psychopharmacol. 2011, 26:404-411.
178. Spiga R., Huang D.B., Meisch R.A., Grabowski J. Human methadone self-administration: effects of diazepam pretreatment. Exp. Clin. Psychopharmacol. 2001, 9:40-46.
179. Spragg S.D.S. Morphine addiction in chimpanzees. Comp. Psychol. Monogr. 1940, 15:1-132.
180. Spyraki C., Kazandjian A., Varonos D. Diazepam-induced place preference conditioning: appetitive and anti-aversive properties. Psychopharmacology 1985, 87:225-232.
181. Stenhouse G., Grieve J.H. Drug-related deaths in Grampian, Scotland. Scott. Med. J. 2003, 48:111-113.
182. Stitzer M.L., Griffiths R.R., McLeIlan A.T., Grabowski J., Hawthorne J.W. Diazepam use among methadone maintenance patients: patterns and dosages. Drug Alcohol Depend. 1981, 8:189-199.
183. Strang J. Intravenous benzodiazepine abuse. Br. Med. J. 1984, 289:964.
184. Strang J., Griffiths P., Abbey J., Gossop M. Survey of use of injected benzodiazepines among drug users in Britain. Br. Med. J. 1994, 308:1082.
185. Substance Abuse and Mental Health Services Administration (SAMHSA) Overview of Findings from the 2007 National Survey on Drug Use and Health: National Findings (NSDUH Series H-34, DHHS Publication No. SMA 08-4343) 2008, Retrieved on December 15, 2010 from: http://oas.samhsa.gov/nsduh/2k7nsduh/2k7Results.cfm.
186. Substance Abuse and Mental Health Services Administration (SAMHSA)/Drug Abuse Warning Network, 2009. National Estimates of Drug-Related Emergency Department Visits. HHS Publication No. (SMA) 11-4659, DAWN Series D-35, Rockville, MD.
187. Substance Abuse and Mental Health Services Administration, 2010. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4586 Findings), Rockville, MD.
188. Substance Abuse and Mental Health Services Administration (SAMHSA), 2011a. Center for Behavioral Health Quality and Statistics. The DAWN Report: Drug-Related Emergency Department Visits Attributed to Intentional Poisoning, Rockville, MD.
189. Substance Abuse and Mental Health Services Administration (SAMHSA), 2011b. Center for Behavioral Health Statistics and Quality. The TEDS Report: Substance Abuse Treatment Admissions for Abuse of Benzodiazepines, Rockville, MD.
190. Szostak C., Finlay J.M., Fibiger H.C. Intravenous self-administration of the short-acting benzodiazepine midazolam in the rat. Neuropharmacology 1987, 26:1673-1676.
191. Teasdale J.P., Bozarth M.A., Stewart J. Body temperature responses to microinjections of morphine in brain sites containing opiate receptors. Soc. Neurosci. Abstr. 1981, 7:799.
192. Thirion X., Lapierre V., Micallef J., Ronflé E., Masut A., Pradel V., Coudert C., Mabriez J.C., Sanmarco J.L. Buprenorphine prescription by general practitioners in a French region. Drug Alcohol Depend. 2002, 65:197-204.
193. Tien L.T., Ma T., Fan L.W., Loh H.H., Ho I.K. Autoradiographic analysis of GABAA receptors in mu-opioid receptor knockout mice. Neurochem. Res. 2007, 32:1891-1897.
194. Trescot A.M., Boswell M.V., Atluri S.L., Hansen H.C., Deer T.R., Abdi S., Jasper J.F., Singh V., Jordan A.E., Johnson B.W., Cicala R.S., Dunbar E.E., Helm S., Varley K.G., Suchdev P.K., Swicegood J.R., Calodney A.K., Ogoke B.A., Minore W.S., Manchikanti L. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006, 9:1-39.
195. Trigo J.M., Martin-García E., Berrendero F., Robledo P., Maldonado R. The endogenous opioid system: a common substrate in drug addiction. Drug Alcohol Depend. 2010, 108:183-194.
196. Tripp G., McNaughton N. Naloxone fails to block the effects of chlordiazepoxide on acquisition and performance of successive discrimination. Psychopharmacology 1987, 91:119-121.
197. Tsuda M., Suzuki T., Misawa M., Nagase H. Involvement of the opioid system in the anxiolytic effects of diazepam in mice. Eur. J. Pharmacol. 1996, 307:7-14.
198. United Nations Drug Control Programme (UNDCP) Annual Report Questionnaire. International Narcotics Control Strategy Report(s) 2001, US Department of State, Washington, Retrieved on January 26, 2011 from: http://www.state.gov/p/inl/rls/nrcrpt/2001/c6085.htm.
199. United Nations Office for Drug Control, Crime Prevention Global Illicit Drug Trends 2002, vol. E.01 XI. 11. United Nations, New York, Retrieved on January 26, 2011 from: http://www.unodc.org/pdf/report_2002-06-26_1/report_2002-06-26_1.pdf.
200. United Nations Office on Drugs and Crime (UNODC) Promoting Health, Security and Justice 2010, United Nations, NY, USA, Retrieved on January 26, 2011 from: http://www.unodc.org/documents/frontpage/UNODC_Annual_Report_2010_LowRes.
201. Vicknasingam B., Mazlan M., Schottenfeld R.S., Chawarski M.C. Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia. Drug Alcohol Depend. 2010, 111:44-49.
202. Vormfelde S.V., Poser W. Death attributed to methadone. Pharmacopsychiatry 2001, 34:217-222.
203. Walker B.M., Ettenberg A. Benzodiazepine modulation of opiate reward. Exp. Clin. Psychopharmacol. 2001, 9:191-197.
204. Walker B.M., Ettenberg A. The effects of alprazolam on conditioned place preferences produced by intravenous heroin. Pharmacol. Biochem. Behav. 2003, 75:75-80.
205. Walker B.M., Ettenberg A. Intra-ventral tegmental area heroin-induced place preferences in rats are potentiated by peripherally administered alprazolam. Pharmacol. Biochem. Behav. 2005, 82:470-477.
206. Walsh S.L., Nuzzo P.A., Lofwall M.R., Holtman J.R. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend. 2008, 98:191-202.
207. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., Bigelow G.E. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Exp. Clin. Psychopharmacol. 1994, 55:569-580.
208. Ward M., Barry J. Opiate-related deaths in Dublin. Irish J. Med. Sci. 2001, 170:35-37.
209. Weerts E.M., Griffiths R.R. Zolpidem self-injection with concurrent physical dependence under conditions of long-term continuous availability in baboons. Behav. Pharmacol. 1998, 9:285-297.
210. Weerts E.M., Kaminski B.J., Gritffiths R.R. Stable low-rate midazolam self-injection with concurrent physical dependence under conditions of long-term continuous availability in baboons. Psychopharmacology 1998, 135:70-81.
211. Weizman T., Gelkopf M., Melamed Y., Adelson M., Bleich A. Treatment of benzodiazepine dependence in methadone maintenance treatment patients: a comparison of two therapeutic modalities and the role of psychiatric comorbidity. Aust. N. Z. J. Psychiatry 2003, 37:458-463.
212. White J.M., Irvine R.J. Mechanisms of fatal opioid overdose. Addiction 1999, 94:961-972.
213. Willner P. Animal models of addiction. Hum. Psychopharmacol. 1997, 12:59-68.
214. Wise R.A. Opiate reward: sites and substrates. Neurosci. Biobehav. Rev. 1989, 13:129-133.
215. Wolf B., Lavezzi W., Sullivan L., Flannagan L. Methadone-related deaths in Palm Beach County. J. Forensic Sci. 2004, 49:375-378.
216. Wolff K. Characterization of methadone overdose: clinical considerations and the scientific evidence. Ther. Drug Monit. 2002, 24:457-470.
217. Woods J.H., Katz J.L., Winger G. Abuse liability of benzodiazepines. Pharmacol. Rev. 1987, 39:251-413.
218. Woods J.H., Katz J.L., Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacol. Rev. 1992, 44:151-347.
219. Yanagita T. Self-administration studies on various dependence producing agents in monkeys. Univ. MI Med. Centre J. 1970, 86:216-224.
220. Yanagita T., Takahashi S. Dependence liability of several sedative-hypnotic agents evaluated in monkeys. J. Pharmacol. Exp. Ther. 1973, 185:307-316.
221. Yoneda Y., Takashima S., Kuriyama K. Possible involvement of GABA in morphine analgesia. Biochem. Pharmacol. 1976, 25:2669-2670.
222. Zador D., Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. Addiction 2000, 95:77-84.
223. Zacharias M., Hunter K.M., Parkinson R. Respiratory effects of intravenous midazolam. N. Z. Dental J. 1996, 92:76-79.
224. Zacny J.P., Lichtor S. Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers. Psychopharmacology 2008, 196:105-116.
225. Zacny J.P., Paice J.A., Coalson D.W. Separate and combined psychopharmacological effects of alprazolam and oxycodone in healthy volunteers. Drug Alc Depend. 2012, 124:274-282.
226. Zonta N., Zambotti F., Vicentini R., Tammiso R., Mantegazza P. Effects of some GABA mimetic drugs on the antinociceptive activity of morphine and fl-endorphin in rats. Naunyn Schmiedebergs Arch. Pharmacol. 1981, 6:231-234.